Role of moxifloxacin for the treatment of commmunity-acquired complicated intra-abdominal infections in Taiwan

Yeu Jun Lau, Yen Hsu Chen, Ching Tai Huang, Wen Sen Lee, Cheng Yi Liu, Jien Wei Liu, Hsiao Dong Liu, Yuarn Jang Lee, Chao Wen Chen, Wen Chien Ko, Po Ren Hsueh

Research output: Contribution to journalReview articlepeer-review

10 Citations (Scopus)


Complicated intra-abdominal infections (cIAIs) are common yet serious infections that can potentially lead to substantial morbidity and morbidity. As an essential adjunct to source control, the goals of antimicrobial therapy are to promote patient recovery, reduce recurrence risk, and prevent antimicrobial resistance. The current international guidelines on the empirical treatment of community-acquired complicated IAIs were published by the Infectious Diseases Society of America (IDSA) and Surgical Infections Society (SIS) in 2010. These guidelines all recommend the use of a fluoroquinolone (ciprofloxacin or levofloxacin) plus metronidazole for mild-to-moderate- and high-severity cases. Moxifloxacin monotherapy is recommended by the current IDSA/SIS guidelines for the treatment of mild-to-moderate complicated IAIs. Moxifloxacin has demonstrated a broad spectrum coverage of both aerobic and anaerobic pathogens, good tissue penetration into the gastrointestinal tract, and a good tolerability profile. Clinical data have demonstrated that moxifloxacin is at least as effective as other standard therapeutic regimens recommended by current clinical guidelines. Due to the high rates of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and fluoroquinolone-resistant Enterobacteriaceae among isolates causing community-acquired IAIs in Asia, any fluoroquinolones (including moxifloxacin) are not recommended as drugs of choice for the empirical treatment of community-acquired IAIs, particularly in countries (China, India, Thailand, and Vietnam) with fluoroquinolone resistance rates among Escherichia coli isolates of >20%. Given the low rates of fluoroquinolone-resistant (

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalJournal of Microbiology, Immunology and Infection
Issue number1
Publication statusPublished - Feb 2012


  • Antimicrobial therapy
  • Complicated intra-abdominal infections
  • Fluoroquinolones
  • Moxifloxacin

ASJC Scopus subject areas

  • Immunology and Allergy
  • General Immunology and Microbiology
  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Role of moxifloxacin for the treatment of commmunity-acquired complicated intra-abdominal infections in Taiwan'. Together they form a unique fingerprint.

Cite this